The American Academy of Neurology (AAN) has published an evidence-based guideline on the assessment and management of psychiatric disorders in individuals with multiple sclerosis (MS). Despite admittedly weak or insufficient evidence, the message from the guideline is strong: Look for emotional disorders—disturbances of mood or affect—in your patients with MS.
As reported in September of this year:
A leading U.S. medical organization is urging its members not prescribe opioid painkillers to patients suffering from fibromyalgia, low back pain or headaches, because the risk of serious side effects outweighs the benefits of pain relief.
“Whereas there is evidence for significant short-term pain relief, there is no substantial evidence for maintenance of pain relief or improved function over long periods of time without incurring serious risk of overdose, dependence, or addiction,” wrote Gary M. Franklin, MD, in a position paper published in Neurology, the official medical journal of the American Academy of Neurology (AAN).
The Academy represents 28,000 neurologists and other healthcare providers who treat a wide variety of neurological disorders, including neuropathy, migraine, multiple sclerosis, epilepsy, and Alzheimer’s disease.